CombiGene has recently raised more than SEK 25 million through two successful warrants, which were excercised at 98.4 percent. At the same time, CombiGene’s two gene therapy projects continue to be developed according to plan and the company’s studies within the epilepsy project have attracted international attention through an article in Frontiers in Molecular Neuroscience by Associate Professor David Woldbye, one of CombiGene’s scientific founders.
Read the full article here: https://www.biostock.se/en/combigene-comments-on-their-latest-progress/
